Rezolute’s lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage development for hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI), including congenital hyperinsulinism (cHI), the most common cause of persistent hypoglycemia in infants and children. Rezolute (RZLT) currently anticipates the base salary for Senior Manager, Scientific Communications & Medical Education role could range from $180,000 to $225,000 and will depend, in part, on the successful candidate’s geographical location and their qualifications for the role, including education and experience.